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Research Article 
 
Abstract 
Coronaviruses are observed in birds and mammals and can be transmitted to humans, leading 
to outbreaks and pandemics. Among the most recent ones are SARS-CoV, MERS-CoV, and 
COVID 19. Thus, the objective was to describe a discussion about coronaviruses, with an 
emphasis on Sars-Cov-2. From the data collected, it can be seen that the current pandemic 
has had impacts on public health and socioeconomic life in more than 170 countries 
worldwide, to date, with tens of millions of people infected and hundreds of thousands of 
deaths. In this regard, prevention actions must be intensified, especially among the most 
vulnerable patients (the elderly and those with comorbidities that affect immunity). In addition, 
new studies should be carried out so that vaccines and antivirals can be implemented for 
application to COVID-19. 
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1. Introduction and Morphology 
Coronaviruses can be observed in birds and wild mammals (birds, bats, rodents, and primates) 
and can be transmitted to domesticated animals, such as camels. From these animals, they 
can contaminate the human being, resulting in respiratory, intestinal, liver, and neurological 
infections. [1, 2, 3, 4] These clinical conditions, lead to restrictions on the circulation of people and 
closing of shops, despite the low lethality, but high dissemination, result in socioeconomic 
impacts in the affected regions. 
This virus belongs to the Coronaviridae family, being described as the etiological agents of the 
most recent infections (SARS-CoV, MERS-CoV, and COVID 19), belonging to the subfamily 
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Betacoronavirus. [5] (Brasil, 2020) Thus, the objective was to describe a discussion about the 
coronavirus, with emphasis on COVID - 19. 
Morphologically, they appear as spherical or plomorphic enveloped particles - Figure 01 [6,7, 8]. 
Anchored in the structure of the viral envelope, glycoproteins are observed, responsible for 
binding to the host cell receptor, as well as hemagglutinin, which contributes to recognition and 
binding to the target cell. These, together with the viral envelope, involve a nucleus that 
contains a positive sense RNA chain associated with nucleoproteins. [6, 7, 9] 
Figure 1: Basic structure of the Coronavirus. 
Source: BioRender.com 
 
2. History of Recent Virus Outbreaks 
Recent viral outbreaks by the coronavirus are believed to be associated with the zoonotic 
transmission (Figure 02), presenting a natural host, such as bats, which transmit to intermediate 
hosts, primates, camels, and other mammals. [4,10]  Considering the most recent outbreaks: 
- Severe Acute Respiratory Syndrome (SARS) occurred between 2002-2003 in Guangdong, 
China, reaching 37 countries, with patients experiencing high fever, headache, body pain, 
cough, and most patients developed viral pneumonia. During this period, more than 8,000 
people were symptomatic, resulting in approximately 800 deaths.[11, 12]  
- Middle East Respiratory Syndrome (MERS) started in the Middle East, spreading to 27 countries 
between 2012 and 2015. The main symptoms seen among 1300 infected people were high 
fever, muscle pain, cough, and a severe respiratory infection that can progress to pneumonia.[1, 
11]  
Figure 2: Coronavirus-associated respiratory syndromes 
Source: BioRender.com 
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Coronavirus Syndrome 2019 (Sars-Cov-2) started in Wuhan, China, apparently spreading from a 
"wet market" to several cities and provinces in China. Being disseminated to dozens of countries 
in the world, the infection is ongoing, affecting tens of millions of people infected and hundreds 
of thousands of deaths. [2, 13]  
 
3. Transmission and Viral Physiopathology 
Coronavirus is commonly transmitted between people from viral particles present in droplets of 
saliva or mucus, expelled through the mouth or nostrils when the person coughs or sneezes. 
Transmission by fecal material containing viral particles is also reported in the literature. 
Transmission can also occur due to the presence of viral particles in the hands or objects 
touched by the patient. [5, 14]  
Figure 3: Replication of the coronavirus 
Source: BioRender.com 
 
After the initial contact with the viral particle, as shown in the illustration of the airway in figure 
03, the virus connects to the target cell receptors through the glycoprotein and hemagglutinin, 
present in the viral envelope. Among the target cell receptors is aminopeptidase-N and a 
receptor containing sialic acid. After this adhesion, the virus is internalized and the viral genome 
is released, followed by its transcription and translation. Then the virus is assembled and the viral 
particle is externalized by sprouting, in which the incorporation of the viral envelope takes 
place. [6, 7, 9] These new particles can invade new cells and spread in the body, generating 
symptoms. 
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4. Symptomatology and Epidemiology 
Coronaviruses after the first contact that result in initial replication, and may be incubated for a 
period between 03 to 07 days, on average. The symptoms start similar to a cold, with a runny 
nose, sneeze, and cough. With the clinical evolution of the disease, fever, cough, body 
weakness/muscle pain and breathing difficulties can be observed - Figure 04. [7, 10, 15]  
In more severe cases, viral pneumonia can be observed leading to life-threatening, among the 
groups at greatest risk are elderly patients, patients with comorbidities that reduce immunity, 
such as HIV, cancers, and diabetes. [2,, 12, 23] 
 
Figure 4: Most frequent symptoms of COVID-19 
Source: BioRender.com 
To date, 12,282,275 cases have been reported with 554,586 deaths, with 65.50 %% of cases 
concentrated in 10 countries listed in Table 1.  
Table 1: Confirm Cases and. Deaths by Country - COVID -19 
Country Total cases Total Deaths 
World 12,282,275 554,586 
USA 3,189,112 135,355 
Brazil 1,727,279 68,355 
India 794,855 21,623 
Russia 707,301 10,843 
Peru 312,911 11,133 
Chile 306,216 6,682 
Spain 300,136 28,401 
UK 287,621 44,602 
Mexico 275,003 32,796 
Iran 250,458 12,305 
Source: 25. Consulted at https://www.worldometers.info/coronavirus/#countries. 
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It is believed that in many countries, underreporting of cases occurs so that the number of cases 
can be between 5 to 10 times greater than those officially registered. This is justified by the low 
level of testing performed in the population.13, 17, 24 
 
5. Treatments and Prevention  
The treatment of COVID - 19 infections does not have, until the moment, specific therapy. Being 
guided by the World Health Organization the home isolation of patients with mild symptoms, 
keeping them under strict monitoring, due to the risk of worsening in the clinical picture. For 
those with clinical complications, supportive treatment that includes mechanical ventilation 
and renal support can be used [5, 16,17]   
Although there is currently no specific, effective antiviral therapy, some studies have 
investigated the potential use of lopinavir, ritonavir, and favipiravir. Lopinavir and ritonavir are 
protease inhibitors and are used mainly in antiretroviral therapy, for example in the treatment of 
HIV. The protease inhibition of COVID 19 would occur so that viral replication would be 
minimized, being useful mainly in cases of viral pneumonia. [18, 19]   
Favipiravir in turn is converted in the body to ribofuranosyl triphosphate, which starts to inhibit 
viral RNA polymerase, being used for example in some influenza infections. [20] Through the 
inhibition of viral RNA polymerase, this drug can be used at the beginning of the disease, 
mitigating the risks of clinical worsening, such as viral pneumonia. [19, 21]   
There are also recommendations regarding therapeutic restrictions, among which the use of 
corticosteroids, except in clinical indications, as it can increase the time of elimination of the 
virus. In addition, there is evidence that the application of corticosteroids in patients with SARS, 
pulmonary inflammation could be improved, on the other hand, immune suppression occurred, 
so that the severity of the infection occurred, requiring a longer hospital stay with mechanical 
ventilation and renal support. [17, 22]   
Regarding prevention, so far there are no vaccines for COVID-19, and WHO recommends 
active surveillance of new cases and strict monitoring of their contacts. In addition to the home 
isolation of patients with mild conditions and educational campaigns aimed at the general 
public, which include: frequent hand washing, cough and sneeze etiquette, avoid 
consumption of raw or undercooked animal products, avoid close contact, and use personal 
protective equipment (eg masks) when visiting public places. Such care should be reinforced 
for more vulnerable individuals with the elderly and those with comorbidities that lead to 
reduced immunity [5, 13, 22, 24]  
In addition to the clinical symptoms, to be classified among a possible infected person, the 
individual must have traveled to the places where the virus is most spread or have contacted 
an infected person or a suspected case. Thus, it is recommended that biosafety measures be 
taken by professionals and perform procedures for the disposal of other diseases. 
In addition, some countries have already implemented measures to restrict the movement of 
people, close borders, and trade, resulting in negative socioeconomic impacts in these 
locations, with the health authorities considering essential measures to spread COVID-19. 
 
6. Conclusion 
From the data collected in this study, it was possible to present points about the biology, 
replication, transmission, and therapy of the coronavirus, focusing on COVID - 19. This 
pandemic, already affects hundreds of countries, with thousands of deaths being observed, in 
addition to the impacts socio-economic conditions resulting from restrictions on the movement 
of people, closing borders, and trade. 
In this regard, prevention actions must be intensified, especially among the most vulnerable 
patients (the elderly and those with comorbidities that affect immunity). In addition, new studies 
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should be carried out so that vaccines and antivirals can be implemented for application to 
COVID-19. 
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